FDA Approves ‘Priority Review’ Of Experimental Lung Cancer Drug
The San Francisco-based Genentech's drug is a checkpoint inhibitor, designed to remove the brakes that tumor cells trick the immune system into applying in order to avoid detection and attack.
The San Francisco Business Times:
Genentech Moves To Drug-Approval Fast Lane As Immunotherapy Speeds Up
An experimental lung cancer drug from Genentech Inc. shaved months off the drug-approval process, the company said Monday, as the field of cancer immunotherapy continues to accelerate. (Leuty, 4/11)